IFNAR1 and systemic lupus erythematosus: Inhibition of IFN signaling with the anti-IFNAR1 antibody anifrolumab has produced clinical improvement in SLE and received regulatory approval, demonstrating that IFN activity drives pathology in at least a subset of patients [176].